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Aims
• This work is funded by the National Institutes of Health through Grant R01 
AI 77706-01
– Immune System Biological Networks:  A Case Study in Improved Data 
Integration & Analysis
• Aim 1: Create an ontology-based representation of host-pathogen 
interactions, focusing on Staphylococcus aureus bacteremia.
• Aim 2: Empirically test the ability of the ontology-based representation 
created in Aim 1 to improve the analysis and interpretation of clinical 
data.
• Aim 3. Empirically test the impact of the ontology-based representation 
created in Aim 1 on understanding Staphylococcus aureus pathogenesis, 
on identifying novel therapeutic targets, and on improving patient 
management.N
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Outline
I. Introduction to IDO
II. Resistance phenomena and their ontological 
representation
III. Case Study: The antibiotic resistance of MRSa
IV. Formalization into triples
V. A definition for protective resistance
VI. Conclusion
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Infectious Disease Ontology (IDO)
• An domain ontology extending BFO 
• An interoperable part of the OBO foundry.  
• Top-level IDO: A core upper ontology for the entire infectious 
disease domain
– At different biological scales
– From different disciplinary perspectives
– ~200 terms
• IDO-extensions: A family of reference ontologies for specific 
diseases and pathogens (e.g., Staph aureus, Malaria, 
Influenza…)
• See http://www.infectiousdiseaseontology.org and IDO 
consortium invitation
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Dispositional view of disease
 disorder
(independent continuant part of bearer)
 disease course 
(a process aggregate in which disease is realized/manifested)
 physical basis of disease
(qualities inhering in the disorder)
 disease (disposition)
 bearer of disease
(independent continuant)
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Resistance Phenomena
• Examples:
– Resistance of an individual to a disease
– Resistance of a tumor to a treatment
– Resistance of a pathogen to a drug
– Herd immunity of an organism population to a 
– Immunity of an individual to an infectious organism
– Resistance of certain bacteria to UV! 
http://edition.cnn.com/2009/TECH/science/03/17/india.bacteria/
• Resistance as a disposition 
– Different types of bearers at different biological scales
• Several ontologies/terminologies include resistance terms.
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Resistance in existing 
terminologies
• [NCI Thesaurus: C19391] Resistance: Natural or acquired 
mechanisms, functions, activities, or processes exhibited by an 
organism to maintain immunity to, or to resist the effects of, 
an antagonistic agent, e.g., pathogenic microorganism, toxin, 
drug.
• Issues:
– Circular definition: uses ‘resist’ in definition for resistance!
– What is the type: mechanism? function? activity? process?
– Restricted to organism bearer 
– Too many disjunctions to be usefulN
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Desiderata for IDO Representation
• BFO-compatible 
• Positive/active principle
– Don’t characterize resistance by what is not happening
– Use lacks wherever necessary 
• Non-proliferation of relations principle
– don’t propose a trivial relation resistant_to
– work with OBO RO and RO-proposed relations
• Correct granularity
– General enough to cover examples
– Specific enough to be useful
• Pragmatic Concerns: IDO/IDO-extension terms should mirror 
scientific interest in resistance types.
– Example: water-resistant walls are probably also lemonade-resistant, but we 
don’t put ‘lemonade resistance’ in our ontology.
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Resistance the quality vs 
Resistance the disposition
• Resistance disposition 
– possessed in virtue of internal physical 
arrangement of bearer
– not always manifested when borne
– realized in active processes at some physical scale
• Resistance quality 
– a sufficiently low susceptibility
Low susceptibility to x High susceptibility to x
threshold
Resistance  to x
(quality) 
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Dispositions in BFO 2.0
• BFO Disposition
– BFO Capability: a disposition that enables its bearer to 
participate in certain processes.
• BFO Function: a capability which evolved in its bearer or whose 
bearer was designed to have the disposition. 
• Categorical Base/Ground is a BFO Quality
– A disposition at a macroscale is usually conferred on its 
bearer by qualities of parts at a microscale
• This is the utility of dispositions in reasoning
• A chain of dispositions-in-wholes and qualities-in-parts all the way 
down
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Case Study: MRSa
• Methicillin Resistant Staph aureus 
(MRSa)
– A type of Staph aureus 
characterized by resistance to 
methicillin (and other β-lactam 
antibiotics).
– As such, treatment decisions and 
public-health policies hinge on 
detecting MRSa
– Currently: A huge problem for 
healthcare providers…
Source: CDC’s PHIL
Our representation consists of:
1.A set of triples describing the 
entities involved in the resistance of 
MRSa to methicillin.
2.Logical inference rules a reasoner 
might use to justify the resistance.
Then use this formalization to inform 
a general definition for IDO
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The Rise and Antibiotic Resistance in Sa
Year Antibiotic Effectiveness
1943 Penicillin available
1947 First resistant strains reported
1960s Switch to methicillin
1961 Methicillin-resistant strain found in Cairo
1980s Methicillin resistance rising, vancomycin used as a last resort
1992 15% methicillin-resistant
1996 35% methicillin-resistant
2000 50% methicillin-resistant
2002 Vancomycin resistance reported
(from Knobler et al, 2003)
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Staphylococcus aureus (Sa)
MSSa MRSa
HA-MRSa CA-MRSa
UK CA-MRSa
Australian 
CA-MRSa
Specific Strains
{Antibiotic Resistance
{Pathogenesis Location 
Type
{Geographic Region
{Various Differentia
Differentiated 
by:
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Formalizing MRSa Resistance
Domain
1. bacteria is_a organism
2. MRSa is_a bacterium
3. synthesis_of_peptidoglycan is_a process and 
has_participant Penicillin_Binding_Protein (PBP)
4. PBP has_function_realized_as_process
synthesis_of_peptidoglycan
5. Bacterial_cell_wall is_location_of PBP 
6. synthesis_of_peptidoglycan results_in_development_of
canonical bacterial_cell_wall
7. formation_of_bacterial_cell_wall is_a process
8. PBP2a is_a PBP
9. methicillin_PBP_binding_process is_a binding process that 
has_participants methicillin and PBP 
10. affinity_to_methicillin disposition_of some PBP to 
undergo a methicillin_PBP_binding_process that is 
realized in the presence of a methicillin.
11. methicillin_PBP_binding_process negatively_regulates
synthesis_of_peptidoglycan.
12. PBP2a lacks affinity_to_methicillin
13. mecA is_a gene
14. MRSa has_part mecA
15. mecA generically_specifies PBP2a_production
16. PBP2a_production results_in_formation_of PBP2a
Inferences
• (IR1) x is_a y & y is_a z → x is_a z
• (IR2) x has_part y & y has_part z → x has_part z
• (D1) MRSa is_a organism 
• (IR3) o is_a organism & g is_a gene & o has_part g & 
g generically_specifies proc & 
proc results_in_formation_of prod & 
o has_part locp &  locp is_location_of prod) →
o has_part prod located_in locp
• (D2) MRSa has_part PBP2a located_in bacterial_cell_wall 
• (IR4) p lacks disposition to undergo proc1
realized in situation s
& proc1 negatively_regulates proc2 & proc2
has_participant p →
In situation s, p participates_in proc2
• (D3) In the presence of methicillin, PBP2a participates_in
synthesis_of_peptidoglycan.
• (IR5) In situation s, p1 participates_in proc & 
p1 located_in p2 & o has_part p2 →
proc unfolds_in o in situation s.
• (D4) synthesis_of_peptidoglycan unfolds_in MRSa in the 
presence of methicillin.
• (IR6) In situation s, proc unfolds_in o & 
proc results_in_development_of p →
p part_of o in situation s
• (D5) Canonical bacterial_cell_wall part_of MRSa in the 
presence of methicillin.
16 triples + 6 inf rence rules + 5 derived triples
but l t’s look at this in pictu es…
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Why MSSa is Susceptible
MethicillinPBP
Synthesis of Peptidoglycan
Methicillin_PBP_Binding_Process
has_participants
negatively_regulates
part_of
Bacterial_Cell_Wall
Peptidoglycan
N
a
t
u
r
e
 
P
r
e
c
e
d
i
n
g
s
 
:
 
d
o
i
:
1
0
.
1
0
3
8
/
n
p
r
e
.
2
0
0
9
.
3
4
7
5
.
1
 
:
 
P
o
s
t
e
d
 
2
7
 
J
u
l
 
2
0
0
9
Why MRSa is Resistant
MethicillinPBP2a
Synthesis of Peptidoglycan
No Methicillin_PBP_Binding_Process
part_of
Bacterial_Cell_Wall
Peptidoglycan
lacks
affinity_to_methicillin
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IDO’s Protective Resistance
• IDO: Protective resistance is a disposition that 
inheres in an material entity x by virtue of the 
fact that the entity has a part (e.g., a gene 
product), which itself has a disposition to 
ensure a physiologic response of a certain 
degree to a potentially damaging entity y, or 
to prevent the completion of some process 
caused by y, thereby protecting x from or 
mitigating the damaging effects of y.
Allows for both organisms 
and tumors
with the capability to damage
Usually a 
function, but 
may be just a 
capability
e.g., CCR5 mutation prevents the completion 
of HIV inv sion of host T cell
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Conclusions
• Resistance is a very important biological phenomenon…
– Guiding treatment decisions
– Public health policy
• and a very general phenomenon…
– Multi-scale (gene, cell, organ, organism, population)
– Multi-discipline (clinical, biological, epidemiological)
• Whose representation in an ontology is non-trivial
– Even a particular instance of resistance requires many triples for 
description and inference.
– Needs further analysis of lacking a disposition (e.g., lacking the affinity 
to methicillin).
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Thanks!
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